Feedback
Settings

Settings

Goto Application

170 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(IKRKQQLJYBAPQT-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 17
1.20250205243SOLID FORMS OF A NUCLEOSIDE ANALOGUE AND USES THEREOF
US - 26.06.2025
Int.Class A61K 31/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
53having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
 Appl.No 18989013 Applicant Gilead Sciences, Inc. Inventor Stefani Kocevska

The disclosure provides solid forms of the compound of Formula (I) and uses thereof. Also provided are the methods of making the solid forms and pharmaceutical formulations comprising the solid forms.

2.WO/2025/137446SOLID FORMS OF A NUCLEOSIDE ANALOGUE AND USES THEREOF
WO - 26.06.2025
Int.Class C07H 19/23
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14-C07H19/22222
 Appl.No PCT/US2024/061278 Applicant GILEAD SCIENCES, INC. Inventor KOCEVSKA, Stefani
The disclosure provides solid forms of the compound of Formula (I) and uses thereof. Also provided are the methods of making the solid forms and pharmaceutical formulations comprising the solid forms.
3.20250197410COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS
US - 19.06.2025
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No 18938495 Applicant Gilead Sciences, Inc. Inventor Mark J. Bartlett

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

4.120098898低氧诱导因子-1α亚基激活剂在恢复胚胎端粒长度中的应用
CN - 06.06.2025
Int.Class C12N 5/073
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
073Embryonic cells or tissues; Foetal cells or tissues
 Appl.No 202411677402.5 Applicant 南京医科大学 Inventor 胡志斌
本发明公开了低氧诱导因子‑1α亚基激活剂在恢复胚胎端粒长度中的应用，属于生物医药技术领域。本发明对处于不同阶段的胚胎进行单细胞测序，构建Tert基因单细胞调控网络，筛选在早期胚胎发育时期对其特异性产生影响的关键转录因子，且经过一系列实验验证Hif1α通过Tert启动子区的区域2中HRE实现功能，其位于Tert的上游具有转录调控作用，从而对胚胎的端粒长度产生影响。因此，本发明对受精卵进行体外培养时，在胚胎培养的不同阶段加入低氧诱导因子‑1α亚基激活剂，激活Hif1α表达，提高Tert基因表达水平，实现了胚胎的端粒延长，进而使体外培养的胚胎的端粒长度与自然妊娠所得胚胎的端粒长度相当。
5.WO/2025/087207LONG-ACTING ORAL PHARMACEUTICAL COMPRISING HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR AND USE THEREOF
WO - 01.05.2025
Int.Class A61K 31/438
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
438the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
 Appl.No PCT/CN2024/126289 Applicant KIND PHARMACEUTICAL Inventor ZHU, Qi
Disclosed are a long-acting oral pharmaceutical comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and use thereof. Specifically, disclosed is a long-acting oral pharmaceutical formulation comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, adjuvants, or excipients. The long-acting oral pharmaceutical formulation is suitable for administration at intervals of once every one week or longer, making it suitable for long-term administration in the treatment of chronic anemia.
6.WO/2025/087208USE OF HYPOXIA-INDUCIBLE FACTOR-PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) IN RARE ANEMIA
WO - 01.05.2025
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
 Appl.No PCT/CN2024/126291 Applicant KIND PHARMACEUTICAL Inventor DENG, Shaojiang
The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).
7.119868550缺氧诱导因子-脯酰胺羟基化酶抑制剂（HIF-PHI）在罕见贫血中的应用
CN - 25.04.2025
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No 202411479661.7 Applicant 杭州安道药业有限公司 Inventor 邓绍江
本申请涉及缺氧诱导因子‑脯酰胺羟基化酶抑制剂(HIF‑PHI)在罕见贫血中的应用。具体地，本申请公开了某些缺氧诱导因子‑脯酰胺羟基化酶抑制剂(HIF‑PHI)在治疗骨髓增生异常综合征贫血(MDS贫血)、β‑地中海贫血(β地贫)和/或镰状细胞疾病(镰刀型贫血、SCD贫血)中的应用。
8.119868549含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用
CN - 25.04.2025
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No 202411479021.6 Applicant 杭州安道药业有限公司 Inventor 朱奇
本申请涉及含有缺氧诱导因子‑脯酰胺羟基化酶抑制剂(HIF‑PHI)的长效口服药物及其应用。具体地，本申请公开了一种长效口服药物制剂，其含有缺氧诱导因子‑脯酰胺羟基化酶抑制剂(HIF‑PHI)或其可药用的盐以及一种或多种药学上可接受的载体、佐剂或赋形剂，该长效口服药物制剂适于以一周或更长时间一次的给药间隔给药，从而适于在慢性贫血的治疗中长期给药。
9.20250129170EPO RECEPTOR AGONISTS AND ANTAGONISTS
US - 24.04.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 18844732 Applicant ImmunEdge, Inc. Inventor Bo YU

The present disclosure provides EPO analogs, anti-EPOR antibodies, anti-EPO antibodies, and fragments thereof that specifically bind to the hetero-EPOR or homo-EPOR or EPO with high affinity. Also provided herein are engineered EPOs. The EPO analogs, anti-EPOR antibodies, anti-EPO antibodies, and/or engineered EPOs can be used to treat patients.

10.WO/2025/078388AGONISTS OF THE BETA-3 ADRENERGIC RECEPTOR FOR USE IN PROMOTING THE MATURATION OF NERVE TISSUE
WO - 17.04.2025
Int.Class A61K 31/195
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
 Appl.No PCT/EP2024/078317 Applicant UNIVERSITÀ DI PISA Inventor FILIPPI, Luca
The present invention relates to a beta- 3 adrenergic receptor agonist or activator for use in accelerating neuronal maturation and in the treatment and/or prevention of diseases of the central and peripheral nervous system and a pharmaceutical composition thereof.
# -